注射用尤瑞克林联合双抗血小板治疗早期急性脑梗死的临床疗效观察

发布时间：2018-05-07 03:15

本文选题：尤瑞克林 + 双抗血小板　；参考：《南京医科大学学报(自然科学版)》2016年04期

【摘要】：目的 :分析急性脑梗死患者使用尤瑞克林联合双抗血小板治疗后的临床疗效。方法 :将2013—2014年本院收治的符合入选条件的110例急性脑梗死患者随机分为分为治疗组和对照组,每组55例。两组均给予相同的基础治疗,治疗组给予氯吡格雷+阿司匹林双抗血小板治疗,另加用尤瑞克林,1次/d;对照组仅给予氯吡格雷+阿司匹林双抗血小板治疗,于治疗前及治疗后14 d,按照美国国立卫生院卒中量表(the National Institutes of Health stroke scale,NIHSS)评分对两组患者进行神经功能缺损程度评定,并用Barthel指数(BI)评分评定日常生活能力,比较两组的临床疗效。结果:治疗组NIHSS较对照组下降明显(P0.05),BI评分,较对照组改善显著(P0.05),治疗组疗效明显优于对照组,且无明显不良反应。结论 :尤瑞克林联合双抗血小板治疗早期急性脑梗死安全有效。
[Abstract]:Objective: to analyze the clinical effect of eurexine combined with double anti-platelet therapy in patients with acute cerebral infarction. Methods: 110 patients with acute cerebral infarction admitted in our hospital from 2013 to 2014 were randomly divided into treatment group (n = 55) and control group (n = 55). Both groups were given the same basic treatment, the treatment group received clopidogrel aspirin double antiplatelet therapy, and the control group received clopidogrel aspirin double antiplatelet therapy. Before and 14 days after treatment, according to the National Institutes of Health stroke scale NIHSS, the patients in the two groups were assessed for the degree of neurological impairment, and the ability of daily living (ADL) was evaluated with the Barthel index (BI) score. The clinical efficacy of the two groups was compared. Results: compared with the control group, the NIHSS in the treatment group decreased significantly (P 0.05) and the score was significantly improved compared with the control group (P 0.05). The curative effect of the treatment group was significantly better than that of the control group, and there was no obvious adverse reaction in the treatment group. Conclusion: Urethrin combined with double anti-platelet therapy is safe and effective in the treatment of early acute cerebral infarction.
【作者单位】：南通大学附属医院神经内科;南通大学附属医院普外科;
【分类号】：R743.3

【相似文献】